Guangji Pharmaceutical (000952) Limit-Up Reason and Market Analysis on November 24, 2025

Guangji Pharmaceutical (000952), as a major global supplier of vitamin B2 [0], hit the limit-up on November 24, 2025, with a closing price of 7.83 yuan, an increase of 9.97%, and a total market value of 2.715 billion yuan [0]. This limit-up is the result of multiple positive factors working together:

1. Governance Optimization
   : The company appointed a new employee representative director on November 14, 2025, strengthened the functions of the audit committee [1], and improved governance transparency.
2. Preparation Business Growth
   : The 2025 third-quarter report shows that preparation revenue increased by 63% year-on-year [0], becoming an important growth driver for performance.
3. R&D Breakthrough
   : Riboflavin products obtained DMF registration and European market access, R&D of products such as 2-Deoxy-D-glucose made progress, and the approval of captopril API promoted the API-preparation integration strategy [1][0].
4. Market Demand Driver
   : Rising demand for vitamins and enhanced market expectations for influenza-related products [2] supported the sales of the company’s core products.
   In terms of market performance that day, the main funds had a net purchase of 19.4132 million yuan [3], and the sealing order funds reached 30.018 million yuan [4], reflecting investors’ confidence in the company’s prospects.

• Significant成效 of the company’s strategic transformation: The API-preparation integration layout (such as the approval of captopril) and international market expansion (DMF registration) will enhance competitiveness in the long term [0][1].
• Positive cycle between governance optimization and business growth: Strengthening internal management helps release operational efficiency and promote sustained growth of preparation and other businesses [1].
• Resonance between market sentiment and fundamentals: Short-term demand (influenza, vitamins) combined with long-term strategies (R&D, integration) drives stock price growth [2][0].

• Opportunities
  :
  1. With the arrival of the flu season, demand for related products is expected to further increase [2].
  2. The supply and demand pattern of the vitamin market has improved, with great potential for price upward movement [0].
  3. The API-preparation integration strategy opens up new growth space [1].
• Risks
  :
  1. Short-term market fluctuation risk: Profit-taking may occur after the limit-up [0].
  2. Intensified industry competition: New entrants or price wars in the vitamin field may affect profits [0].
  3. R&D progress is less than expected: Delays in new product launches may affect long-term growth [0].

Guangji Pharmaceutical (000952)'s limit-up on November 24, 2025 is the result of improved fundamentals and market demand. The company’s positive changes in governance, R&D, business structure, etc., combined with rising demand for vitamins and influenza-related products, drove the stock price performance. Investors should pay attention to long-term factors such as the progress of the company’s API-preparation integration, R&D achievement transformation, and changes in market demand, while noting the risk of short-term market fluctuations.